SG Americas Securities LLC Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

SG Americas Securities LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 31.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,086 shares of the company’s stock after purchasing an additional 7,141 shares during the quarter. SG Americas Securities LLC’s holdings in Nurix Therapeutics were worth $567,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Squarepoint Ops LLC purchased a new position in Nurix Therapeutics during the second quarter worth about $601,000. AQR Capital Management LLC lifted its holdings in shares of Nurix Therapeutics by 76.8% in the 2nd quarter. AQR Capital Management LLC now owns 21,296 shares of the company’s stock worth $444,000 after acquiring an additional 9,254 shares during the last quarter. Millennium Management LLC boosted its position in shares of Nurix Therapeutics by 60.2% during the 2nd quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock worth $12,514,000 after purchasing an additional 225,374 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Nurix Therapeutics by 25.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock valued at $479,000 after purchasing an additional 4,583 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky purchased a new stake in Nurix Therapeutics in the second quarter valued at approximately $578,000.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $19.71 on Friday. Nurix Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $29.56. The firm has a market capitalization of $1.50 billion, a PE ratio of -6.82 and a beta of 2.14. The business’s fifty day moving average price is $20.09 and its 200 day moving average price is $22.39.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. As a group, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the sale, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

NRIX has been the subject of several research analyst reports. BTIG Research initiated coverage on Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target for the company. Royal Bank of Canada raised their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. cut their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.71.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.